These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
202 related articles for article (PubMed ID: 2035258)
1. Effect of dopamine agonist medication on prolactin producing pituitary adenomas. A morphological study including immunocytochemistry, electron microscopy and in situ hybridization. Kovacs K; Stefaneanu L; Horvath E; Lloyd RV; Lancranjan I; Buchfelder M; Fahlbusch R Virchows Arch A Pathol Anat Histopathol; 1991; 418(5):439-46. PubMed ID: 2035258 [TBL] [Abstract][Full Text] [Related]
2. Prolactin-producing pituitary tumor: resistance to dopamine agonist therapy. Case report. Kovacs K; Stefaneanu L; Horvath E; Buchfelder M; Fahlbusch R; Becker W J Neurosurg; 1995 May; 82(5):886-90. PubMed ID: 7714616 [TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical expression of SNAP-25 protein in adenomas of the human pituitary. Rotondo F; Kovacs K; Scheithauer BW; Horvath E; Bell CD; Lloyd RV; Cusimano M Appl Immunohistochem Mol Morphol; 2008 Oct; 16(5):477-81. PubMed ID: 18633321 [TBL] [Abstract][Full Text] [Related]
4. Spontaneous sparsely-granulated prolactin-producing pituitary adenomas in aging rats. A prospective study of the effect of bromocriptine. McComb DJ; Hellmann P; Kovacs K; Scott D; Evans WS; Burdman JA; Thorner MO Neuroendocrinology; 1985 Sep; 41(3):201-11. PubMed ID: 4047338 [TBL] [Abstract][Full Text] [Related]
5. Clinical and morphological findings in two cases of bromocriptine-treated prolactinomas. Anniko M; Wersäll J Acta Pathol Microbiol Scand A; 1981 Jan; 89(1):41-7. PubMed ID: 7223426 [TBL] [Abstract][Full Text] [Related]
6. Prolactin receptor messenger ribonucleic acid in normal and neoplastic human pituitary tissues. Jin L; Qian X; Kulig E; Scheithauer BW; Calle-Rodrigue R; Abboud C; Davis DH; Kovacs K; Lloyd RV J Clin Endocrinol Metab; 1997 Mar; 82(3):963-8. PubMed ID: 9062514 [TBL] [Abstract][Full Text] [Related]
7. Hyperprolactinemic response after bromocriptine withdrawal in women with prolactin-secreting pituitary tumors. Maxson WS; Dudzinski M; Handwerger SH; Hammond CB Fertil Steril; 1984 Feb; 41(2):218-23. PubMed ID: 6698215 [TBL] [Abstract][Full Text] [Related]
8. Hormone secretion by cell culture of human GH-PRL secreting pituitary adenomas: effects of bromocriptine. Lei T; Bai X; Liu K; Hu W; Xue D; Jiang X J Tongji Med Univ; 1998; 18(3):161-3. PubMed ID: 10806816 [TBL] [Abstract][Full Text] [Related]
9. Pathological study of thyrotropin-secreting pituitary adenoma: plurihormonality and medical treatment. Teramoto A; Sanno N; Tahara S; Osamura YR Acta Neuropathol; 2004 Aug; 108(2):147-53. PubMed ID: 15185102 [TBL] [Abstract][Full Text] [Related]
10. Effect of tamoxifen administration on prolactin release by invasive prolactin-secreting pituitary adenomas. Lamberts SW; Verleun T; Oosterom R Neuroendocrinology; 1982; 34(5):339-42. PubMed ID: 7078703 [TBL] [Abstract][Full Text] [Related]
11. Perifusion studies of bromocriptine-treated and untreated macroprolactinomas: effects of dopamine, bromocriptine and TRH. Bevan JS; Burke CW Clin Endocrinol (Oxf); 1989 Jun; 30(6):667-80. PubMed ID: 2512041 [TBL] [Abstract][Full Text] [Related]
12. Bromocriptine reduces the size of cells in prolactin-secreting pituitary adenomas. Landolt AM; Minder H; Osterwalder V; Landolt TA Experientia; 1983 Jun; 39(6):625-6. PubMed ID: 6852202 [TBL] [Abstract][Full Text] [Related]
13. Tissue kallikrein is associated with prolactin-secreting cells within human growth hormone-secreting adenomas. Jones TH; Figueroa CD; Smith CM; Cullen DR; Bhoola KD J Endocrinol; 1992 Jul; 134(1):149-54. PubMed ID: 1500840 [TBL] [Abstract][Full Text] [Related]
14. Rapid decrease in amino acid metabolism in prolactin-secreting pituitary adenomas after bromocriptine treatment: a PET study. Bergström M; Muhr C; Lundberg PO; Bergström K; Gee AD; Fasth KJ; Långström B J Comput Assist Tomogr; 1987; 11(5):815-9. PubMed ID: 3498743 [TBL] [Abstract][Full Text] [Related]
15. Effects of bromocriptine on prolactin-secreting pituitary adenomas. Mechanism of reduction in tumor size evaluated by light and electron microscopic, immunohistochemical, and morphometric analysis. Mori H; Mori S; Saitoh Y; Arita N; Aono T; Uozumi T; Mogami H; Matsumoto K Cancer; 1985 Jul; 56(2):230-8. PubMed ID: 4005795 [TBL] [Abstract][Full Text] [Related]
16. Macroprolactinomas and functionless pituitary tumours. Immunostaining and effect of dopamine agonist therapy. Gasser RW; Mueller-Holzner E; Skrabal F; Finkenstedt G; Mayr U; Tabarelli M; Spoendlin H; Grunert V; Twerdy K Acta Endocrinol (Copenh); 1987 Oct; 116(2):253-9. PubMed ID: 3116800 [TBL] [Abstract][Full Text] [Related]
17. Morphologic changes of prolactin-producing pituitary adenomas after short treatment with dopamine agonists. Kontogeorgos G; Horvath E; Kovacs K; Coire C; Lloyd RV; Scheithauer BW; Smyth HS Acta Neuropathol; 2006 Jan; 111(1):46-52. PubMed ID: 16328513 [TBL] [Abstract][Full Text] [Related]
18. Demonstration of specific dopamine receptors on human pituitary adenomas. Koga M; Nakao H; Arao M; Sato B; Noma K; Morimoto Y; Kishimoto S; Mori S; Uozumi T Acta Endocrinol (Copenh); 1987 Apr; 114(4):595-602. PubMed ID: 3577589 [TBL] [Abstract][Full Text] [Related]
19. Transformation of a human mixed GH-PRL adenoma cell population in response to long-term bromocriptine treatment. Bácsy E; Fazekas I; Slowik F; Pásztor E; Czirják S Folia Histochem Cytobiol; 1997; 35(2):69-74. PubMed ID: 9151080 [TBL] [Abstract][Full Text] [Related]
20. Pathology of prolactin cell adenomas of the human pituitary. Horvath E; Kovacs K Semin Diagn Pathol; 1986 Feb; 3(1):4-17. PubMed ID: 3303229 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]